Arkolith/Insider Trading/ARQT/Form 4

Watanabe Todd

See Remarks, DirectorArcutis Biotherapeutics, Inc. (ARQT) · full profile →Form 4 · filed Feb 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$506K
Net Open-Market Flow
-$506K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)20K$25.50$506K721K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-005570) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML